No matches

3 search results for: prognostic features

Pulmonology

What Differentiates COPD Exacerbations From Asthma Exacerbations?

2 min

expert video

Join global expert Dr. Eric Bateman as he discusses how exacerbations in patients with COPD are different than exacerbations in patients with asthma.

Type 2 Inflammation

2025 ADVENT Forum | Joint Plenary Session: A View into the Life of Our Patients Video

46 min

expert video

This cross-TA plenary session addressed challenges in type 2 inflammation-driven diseases. Esteemed faculty, including Profs Klaus Rabe, Sharon Dell, Anju Peters, Milli Gupta, Eric Simpson, Stella Lee, and moderator Oscar Palomares, discussed strategies to enhance quality of life, reduce disease burden, and prioritize patient-centered care.

Pulmonology

Uncovering the Impact of Moderate COPD Exacerbations

5 min

interactivity

Understand the impact of moderate chronic obstructive pulmonary disease (COPD) exacerbations on future exacerbation risk, lung function decline, mortality, and patient quality of life.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ChileChange country/region